



D.0.5 Minutes from Interim meeting 2021

WP0 Project coordination

Responsible Partner: DTU

Contributing partners: ANSES, SSI, UCM, INRA, IP, APHA, ISS, IZSAM, IZSLER, RIVM, WBVR, PIWET, SLV, FOHM, SVA



GENERAL INFORMATION

European Joint Programme full title	Promoting One Health in Europe through joint actions on foodborne zoonoses, antimicrobial resistance and emerging microbiological hazards
European Joint Programme acronym	One Health EJP
Funding	This project has received funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement No 773830.
Grant Agreement	Grant agreement n° 773830
Start Date	01/01/2018
Duration	60 Months

DOCUMENT MANAGEMENT

JIP/JRP deliverable	D.0.5		
Project Acronym	EJP CARE		
Author	Susanne Karlsmose Pedersen, DTU		
Other contributors	WP leaders (DTU, SSI, ANSES, IP)		
Due month of the report	M38 (February 2021)		
Actual submission month	M38 (February 2021)		
Type <i>R: Document, report DEC: Websites, patent filings, videos, etc.; OTHER</i>	R Save date: 5-May-21		
Dissemination level <i>PU: Public (default) CO: confidential, only for members of the consortium (including the Commission Services)</i>	PU This is the default setting. If this project deliverable should be confidential, please add justification here (may be assessed by PMT):		
Dissemination <i>Author's suggestion to inform the following possible interested parties.</i>	<div style="display: flex; flex-wrap: wrap;"> <div style="width: 33%;">OHEJP WP 1 <input type="checkbox"/></div> <div style="width: 33%;">OHEJP WP 2 <input type="checkbox"/></div> <div style="width: 33%;">OHEJP WP 3 <input checked="" type="checkbox"/></div> <div style="width: 33%;">OHEJP WP 4 <input checked="" type="checkbox"/></div> <div style="width: 33%;">OHEJP WP 5 <input type="checkbox"/></div> <div style="width: 33%;">OHEJP WP 6 <input type="checkbox"/></div> <div style="width: 33%;">OHEJP WP 7 <input type="checkbox"/></div> <div style="width: 33%;">Project Management Team <input checked="" type="checkbox"/></div> <div style="width: 33%;">Communication Team <input type="checkbox"/></div> <div style="width: 33%;">Scientific Steering Board <input type="checkbox"/></div> <div style="width: 33%;">National Stakeholders/Program Owners Committee <input type="checkbox"/></div> <div style="width: 33%;">EFSA <input type="checkbox"/></div> <div style="width: 33%;">ECDC <input type="checkbox"/></div> <div style="width: 33%;">Other international stakeholder(s):</div> </div> <div style="margin-top: 10px;">Social Media:</div> <div style="margin-top: 10px;">Other recipient(s):</div>		



MINUTES - EJP CARE INTERIM MEETING 2021

3-4 February 2021 (virtual meeting)

Participants

All EJP CARE consortium partners were represented at the meeting:

DTU National Food Institute (EURL-AR) (Denmark), Statens Serum Institut (SSI) (Denmark), Istituto Superiore di Sanità (ISS) (EURL STEC) (Italy), Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "G. Caporale" (IZSAM) (Italy), Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZSLER) (Italy), National Institute for Public Health and Environment (RIVM) (EURL SALM) (the Netherlands), WUR – WBVR (the Netherlands), The Public Health Agency of Sweden (Sweden), National Veterinary Institute (EURL CAMP) (Sweden), Swedish National Food Agency (Sweden), National Veterinary Research Institute, Puławy (NVRI) (Poland), VISAVET – UCM (Spain), French Agency for Food, Environmental and Occupational Health & Safety ANSES (EURL LIST and Risk Assessment Department) (France), Institut Pasteur (France), French National Institute for Agricultural Research (INRAE) (France), Animal & Plant Health Agency (APHA) (United Kingdom).

Minutes taker: Susanne Karlsrose Pedersen, DTU, Denmark

3 February 2021 – Day 1

Rene Hendriksen, DTU, opened the two-day virtual meeting by welcoming the meeting participants followed by a short introduction of the participants at the virtual meeting.

Karin Artursson (SVA, OHEJP WP4) gave an overview of OHEJP projects and presented links between them, i.e. introduced to the Joint Integrative Projects (JIPs) (of which EJP CARE is one) and presented Cogwheel Workshops (CWs) that aim to identify synergies, joint priorities and opportunities for collaboration and Thematic Integrative Meetings (TIMs) that aim to facilitate integration across the OHEJP domains (within themes).

Additional partners that can be included in ongoing JIPs have been identified. As for EJP CARE, it was agreed that these will receive an invitation to participate in the PT's that WP1 will set up in 2021.

Karin touched down on the EJP CARE Data Management Plan (DMP) that needs to present all information on how to access the data and the results generated in the project.

Karin highlighted that there is now a 'Scientific Publication policy ver.2' (simpler than the previous version). This has been circulated to all EJP CARE partners (email from Rene Hendriksen on 02.02.2021).

Rene Hendriksen (DTU) walked through the progress and the outcomes of the EJP CARE and presented the deliverables that are now in place as well as those that are upcoming. In addition, the list of identified risks and the proposed action relating to these were discussed. Moreover, Rene stressed that it is the WP leads' responsibility to follow-up and ensure that all described tasks in the proposal are carried out and deliverables finalized according to plan. Should it be necessary to make adjustments to the plan, this must be brought up with OHEJP WP4 together with a plan for a new due date for the deliverable in question.

EJP CARE look forward to adding a contact person at ECDC to the contact list (*subsequent to the meeting, Marius Linkevicius has been identified as the ECDC contact person for EJP CARE*).

All four WP leads introduced the progress and preliminary outcome of their WP.



For WP 1, WP lead Jeppe Boel (SSI) presented the status in relation to developing guidance for cross-sectorial PT's aimed at trialing the collaborative systems' ability to solve food-borne outbreaks and in relation to ensuring alignment of the methodologies used in the different sectors. Invitations for the three pilot PTs have been circulated to the EJP CARE partners (January 2021) and suggested dispatch for the first pilot PT (ST1-PT1; on isolation/detection and characterization of pathogens) is April 2021.

Lucas Wijnands (RIVM) supplemented by presenting deliverable D.1.1 'Report: Mapping of existing and proposals for new PT schemes'. The report concluded that there are many PT's related to phenotypic methods, and also an increasing number related to molecular methods. As of now, only few PT's have been identified relating to WGS/NGS initiatives, though the number is increasing. The aim of WP1 to design, construct and organize pilot PTs/EQAs based on WGS/NGS will therefore be a valuable outcome of EJP CARE.

For WP 2, WP lead **Olivier Chesneau (IP)** presented the modus operandi for setting up the database. At the kick-off meeting, focus organisms were selected and since then, work has been ongoing to obtain an overview of the inventory based on resources at the EJP CARE partners. Olivier stressed that the faster we work now, the more time we will have to get additional isolates and enrich the collected information.

Anne Brisabois (ANSES) supplemented by adding some details about the collection of reference material (EUROpanelOH). The reference material is needed for quality control, validation of methods and as standards in PTs and we wish to deliver a large collection of well-characterized bacterial strains and genomes for effective QC in food safety and public health protection. A list of minimal data has been defined regarding the reference material in the inventory that contains nine zoonotic pathogens currently presenting 2719 bacterial strains. A gap analysis is ongoing, aiming to identify where further investigations and characterization is needed (strains with certain reference criteria, WGS of available strains, MALDI-ToF spectra of available strains). Finally, this will feed into the work of WP3 that creates a catalogue of the reference strains.

For WP 3, WP lead **Michel-Yves Mistou (INRAE)** presented the ongoing work in relation to 'Access and sustainability of well-defined microbial reference materials (RM)'. A structure for an information system for making RM more widely accessible and visible has been developed, and work is ongoing to study the useful and necessary functionalities for setting up searchable online RMs catalogues. Forum Shah who has been recruited for 12 months (Feb, 2021-Feb, 2022) to implement the technical solution (Biolumics) was presented to the participants. It was discussed whether there are conflicts with existing databases/infrastructures, or potential synergies, and this will be further looked into by WP4. In relation to ensuring the long-term sustainability of RM collections, work is ongoing to setup a training session.

For WP 4, WP lead **Laurent Guillier (ANSES)** presented the risk assessment activities and the methodology related to quantitative risk assessment. Aiming to investigate and benchmark the availability and quality of the existing (meta-)data relevant for risk assessment, WP4 is working to harmonize data with the purpose to increase the accessibility and for higher comparability. A survey on (meta-)data relevant for risk assessment has been developed and collaboration is ongoing with databases and initiatives already in place in EU. WP4 is collaborating with the other EJP CARE WP's to define strain selection strategies for phenotypic or genomics studies as well as working on an R-tool for sampling strains based on metadata in a One Health context.

Hein Imberechts (SCIENSANO, OHEJP) talked about 'the One Health EJP as an opportunity for cross-sector collaboration'. Based on key facts of the OHEJP he walked us through the organization, objectives and opportunities of the project setup aiming to create and consolidate reference laboratory functions. For the JIPs, like EJP CARE, the deliverables are expected to become integrated into the work processes of project partners and to have a long term outcome. All data produced in the OHEJP project must be presented in the project DMP, on OpenAIRE and Zenodo.

Finally, Hein reminded of the Annual Scientific meeting 2021 that will take place in Copenhagen 9-11 June 2021 (<https://ohejp2021.com/>).



Kaye Burgess (TEAGASC, DiSCoVeR project) presented the DiSCoVeR project (Discovering the sources of *Salmonella*, *Campylobacter*, VTEC and antimicrobial resistance) which aims to prioritise effective control and prevention of infectious diseases by using source tracking and attribution studies to analyze the burden of the different infectious diseases, look into what causes the problems, consider the options for intervention and attempt to measure the effect of interventions. One of the aims of the DiSCoVeR project is to develop new models accounting for multi-directionality of transmission incl. transmission among reservoirs and within the human population, including both phenotypic and genomic typing techniques and including explanatory epidemiological data. The project will setup a platform/hub to share and standardize microbiological and epidemiological data and models to perform source attribution analyses.

4 February 2021 – Day 2

The second meeting day started with introduction to breakout sessions organized in two parallel sessions for which all meeting participants were asked to select to participate in discussions related to either WP1 or WP2 (session 1), and related to WP3 and WP4 (session 2). The breakout sessions were headed by the WP leads who were tasked with discussing a number of items related their WP:

- 1) Milestones and deliverables for 2021,
- 2) Involvement of each partner in the activities,
- 3) Revision and validation of GANTT chart for the WP,
- 4) Data generated by the WP for the DMP,
- 5) Risks and mitigations (COVID-19-related and others),
- 6) Reflections on links to other OHEJP projects and how to conduct activities in complementary and not in duplication.

In the Appendices, specific notes related to each of the WP's are presented.

The second meeting day ended with a plenary session in which all WP leads presented an extract of the discussions at the breakout session.

Discussions and comments at the plenary session included information from **WP1** that there have been no major changes to the plans already agreed, only, they would set up a meeting to discuss how to set up validation aiming at accrediting the WGS method as a basis for using this method for typing/characterizing bacterial strains. From **WP2** it was stated that the gap analysis (task 2) will be conducted by several sub-groups for each bacterial species and three lists of strains will be established among the inventory according to their availability and characterization, in order to pursue with the task 3 regarding WGS, AMR, Maldi-ToF identification., **WP3** is proceeding with setting up a webtool/database that makes the RM searchable. For this purpose, it is suggested that one representative from each partner participates in the planning (Anne Brisabois and Emmanuelle Helloin will coordinate). Moreover, WP3 concluded that face-to-face training session on mBRCs would be preferable but that the planning of such an event will depend on the evolution of the sanitary situation. Therefore different options will be examine by WPT2 (face to face and online training). Considering the difficulties, the planned date for execution of the training are expected to be delayed. For **WP4**, Laurent walked us through the considerations of the breakout group related to the discussion items. It was decided to postpone D.4.1.2 till June 2021.

Mia Torpdahl (SSI) gave a status related to the Data Management Plan (DMP). The DMP is a living document that presents the collections and data sets that have been produced or processed within EJP CARE (the data themselves are not listed here). Currently we have listed the survey on (meta-)data relevant for risk assessment (WP4), the list of resources relevant for risk assessment (WP4), and the inventory of available RM (WP2). The DMP needs to be further developed and needs to also include planned data. Also: Each provider of RM needs their own post in the DMP.



Finally, time was allocated for **general discussions, risks and mitigations, planning and other considerations.**

Rene Hendriksen highlighted the importance of meeting the milestones and deliverables agreed in the proposal. A GANTT chart detailing all concluded and pending tasks (detailed in microsteps/subtasks and presenting responsible persons) will be helpful in keeping a good overview of the progress. Keep the GANTT charts realistic in relation to due dates. Should some milestones/deliverables need to be postponed, this needs to be captured in the GANTT chart and reported to WP4. Karin Artursson mentioned that new due dates may be needed for some, as complete, final deliverables are preferred (as long as they are not too delayed and as long as other milestones/deliverables do not depend on them). Note also that on the OHEJP website (EJP CARE private group), deliverables that are partially done/living documents may be uploaded. On Zenodo only final, complete deliverables may be uploaded. All WP's were encouraged to setup more satellite meetings to ensure the progress of the WP tasks and to ensure that it is clear who has the responsibility of driving specific tasks forward (WP-lead? Task lead? Others?).

It was highlighted that the final output of WP3 is very dependent of the outcome of WP2.

The possibility of extending the EJP CARE project was discussed. Karin Artursson confirmed that there is a potential opportunity to have the project extended, though this might be relevant for the overarching OHEJP and not for the projects. Further info will be circulated when available.

Karin Artursson mentioned that the collaboration between EJP CARE and OH-HARMONY-CAP is valuable. Rene Hendriksen confirmed that communication is ongoing between the two projects and will consider setting up a more formal meeting setup to ensure that the purpose is met.

Karin Artursson mentioned that the TIM meetings will also bring the two projects together.

Appendices:

- Minutes from WP1 breakout session
- Minutes from WP2 breakout session
- Minutes from WP3 breakout session
- Minutes from WP4 breakout session
- Meeting agenda



Appendix: Minutes from WP1 breakout session

Chair: Jeppe Boel

EJP-OH-CARE WP1: Development of new cross-sectorial PT's – Breakout session

Minutes from breakout session 04.02.2021 09.10-10.25 CET

Participants

Bertrand	Lombard	ANSES
Cecilia	Jernberg	FOHM
Elina	Lahti	SVA
Hilde	Riedel	SLV
Jeppe	Boel	SSI
Indra	Bergval	RIVM
Lucas	Wijnands	RIVM
Darius	Wasył	PIWET
Mike	Brouwer	WBVR
Sally	Hallam	APHA
Paula	Johnson	APHA
Nick	Coldham	APHA
Ewelina	Iwan	PIWET
Rene S.	Hendriksen	DTU

Agenda:

1. General info
2. WP1-T2-ST1 Pilot PT on isolation/detection and characterization of pathogens (Elina Lahti and Cecilia Jernberg)
3. WP1-T2- ST2 Pilot PT on typing/characterization including WGS (Rene Hendriksen and Kees Veldman)
4. WP1-T2- ST3 Pilot PT on outbreak surveillance based on WGS data (Jeppe Boel and Nick Coldham)
5. Should other non-CARE laboratories be invited
6. Co-ordination of execution (time tables for each PT)
7. AOB

Ad 1.

Jeppe discussed the deliverables and milestones for 2021 and mentioned the delivery of all WP1 tasks from all parties involved were on track. The deliverables for the reports from each of the pilots will be due in December 2021 and could they be used to produce scientific papers?

The Gantt chart has not been updated on a regular basis, however this will be updated frequently from now on.



Ad 2.

Elina presented an update to the status of ST1 pilot on isolation/detection and characterization of pathogens. Jeppe asked about the participation outside the core consortium (note:-funding cannot be provided outside of the CARE partners) to date only 3 laboratories (Sweden PH & Vet Labs) have indicated their agreement to participate and it was agreed 3 participants is enough and they can decide whether they tested all the samples in the panel (e.g. in their repertoire) which consisted of *Campylobacter*, *Salmonella* and *Yersinia*.

A risk identified for the pilot is if there is not a cross section of participants it will be a challenge to write the final report so this must be looked into. **Action Elina & Cecilia**

Indra indicated a wish to join this pilot, however with the current COVID situation access to their laboratory is restricted. Based on this Jeppe asked if labs would perform the PT analysis on the day of receipt or if they would get more time? The PT samples could only be stored for 2 – 3 days unless the concept of the PT was changed for example a swab and separate matrix

Rene also wanted DTU to participate and mentioned the reporting aspects do not indicate the methodology i.e. will it be culture, ID etc. Elina mentioned the reporting format has yet to be designed and any input would be welcome

Discussion was also based around contamination level (cfu) for each sample i.e. high or low as would be interesting to include and assess this. PH labs have the highest detection and therefore could be tailored so be more challenging for each sector. 5 samples would be sent in total (not per bacteria).

Mike & Dariusz identified a risk to the pilot dates of the PT as there are currently shortages within the EU community with regards to sourcing consumables (e.g. plastics). Could these dates be altered to avoid bank holidays (e.g. Easter) to possibly mid-May?

Indra also indicated the turnaround time for the PT of 2 weeks was too short especially in when determining/identifying *Salmonella* cultures, therefore extending this time may be possible.

Bertrand mentioned the vials contain different bacteria therefore would they receive additional vials due to the different pre-enrichment methods used for each Bacteria? Elina said there would be enough material in each vial as they would be reconstituted with PBS or SDW.

Jeppe asked Sweden to contact and communicate with the laboratories about their plans for the pilot PT and set up a dialogue by way of a TC and have a Q&A session. **Action Elina & Cecilia**

Ad 3.

Rene presented an update to the status of ST2 Pilot PT on typing/characterization including WGS. In months 37-38 progression is a little behind schedule however once the areas are signed off at director level they will be back on track with regards to genomes. Currently propagating cultures and will launch a meeting with EQA providers and reach out to WP1 for pipelines.

Dariusz asked if consideration had been made for the 'wet' part with regards to some information on quality steps. Rene replied to say questions would be asked throughout the steps, the labs to provide in parallel manual prep and robotic and more than one participant from each lab could join in order to do this.

Rene is to check that the laboratories are signed up to the pilot and did they cover all testing /sector areas? **Action Rene**

Nick discussed the importance of accreditation for each step and the need for a different EQA/PT panel for each step and had this been thought about? Rene acknowledged this as there was need for auto accreditation and this has been discussed at EURL director mtgs. Also a benchmark should be provided for the pipelines to ensure what is being provided is correct.

Nick also said accreditation is very important for stakeholders in the event of legal challenges being made, also there is a need for ongoing PT in order to maintain competence.



Jeppe and Bertrand also said how important accreditation aspect was, Elina expressed an interest in an accreditation discussion. Nick to set up a mtg on how methods should be accredited for all. **Action Nick**

Ad 4.

Jeppe presented an update about the status of ST3 Pilot PT on outbreak surveillance based on WGS data (this was well received). To summarise this - everything is going to schedule at present.

Ad 5.

Jeppe mentioned the need to ensure the appropriate laboratories were on board for all pilots and each WP leader to check whether laboratories are to join including those not already in the CARE consortium. It is noted again non - CARE partners will not be funded.

Ad6.

Timetables and Gantt chart should be update regularly.

Ad7.

AOB

New mtgs to be set up by sub task leaders for pilot PT's. WP leaders to also set up additional mtgs to discuss project progress, and links to other projects to help avoid duplication of work. **Action all WP/Sub task leaders**

Sally Hallam 04/02/2021



Appendix: Minutes from WP2 breakout session

WP2 - Focus on Task 2: Gap analysis

Chair: Olivier Chesneau and Nalini Rama Rao

19 participants: Antonella Maugliani, Mia Torpdahl, Anne Brisabois, Benoit Doublet, Hanna Skarin, Henk Aarts, Marie-Beatrice Boniotti, Emmanuelle Helloin, Dominique Clermont, Kees Veldman, Forum Shah, Juliana De Oliveira Mota, Laurent Guillier, Magdalena Zajac, Maria Ugarte, Rozenn Dervyn, Susanne Karlsmose, Olivier Chesneau, Nalini Rama Rao

Mailing list WP2- Task 2

olivier.chesneau@pasteur.fr
nalini.ramarao@inrae.fr
antonella.maugliani@iss.it
MTD@ssi.dk
Anne.BRISABOIS@anses.fr
benoit.doublet@inrae.fr
Hanna.skarin@sva.se
henk.aarts@rivm.nl
mariabeatrice.boniotti@izsler.it
emmanuelle.helloin@inrae.fr
dominique.clermont@pasteur.fr
kees.veldman@wur.nl
forum.shah@inrae.fr
Juliana.deoliveiramota@anses.fr
Laurent.GUILLIER@anses.fr
magdalena.zajac@piwet.pulawy.pl
maria.ugarte@ucm.es
rozenn.dervyn@inrae.fr
suska@food.dtu.dk
Valeria.michelacci@iss.it
michel-yves.mistou@inrae.fr

Main objective

[**] Reference material to select among the inventory

[**] Do the gap analysis and identify what is missing to be able to continue with characterization and preparation of strains for BRC/collection integration

Main discussion:

- Global analysis on the Strain Table provided during Task 1.
 - Define the compulsory criteria for the RM strains (to have at the start)
 - Define the other characterization criteria (to obtain).
- Different pathogens -> Different criteria -> Difficult to have a common list -> Experts needed
- Define the reasons of the partners to have entered their strains as RM in the table (why it is relevant)
 - Define the missing characterization of the strains
 - Refine the selection of strains

Main goals and actions:

- Define the compulsory criteria for RM strains: **the strains need to be sharable.**
 - the providers should be willing to share the strains



- the minimum information should be there to fill the MTA and/or Nagoya protocol
- Exception for the strains that are important for PT trials but do not provide these criteria, can be added into the 3rd list?

-Divide the strains into 3 lists

- The “happy few” **essential list**: contained the already well characterized RM strains
- The **need to be there list**: strains we want as RM but with missing characteristics: to be further proceed in task 3
- The **optional list**: would be good to have but not compulsory to be extensively characterized

-Identification of 1 person responsible per species

Salmonella : **Henk Aarts**, Benoit, Anne
Listeria: **Anne Brisabois**/ Sophie Roussel
Campylobacter: **Hanna Skarin**, Susanne K.
E. coli: **Valeria** Michelacci, Benoit
Staphylococcus : **Olivier** and Maria U.
Bacillus cereus: **Nalini** Rama Rao, Olivier
Yersinia: **Maria U.** (maria.ugarte@ucm.es), Olivier

Streptococcus : Kees Veldman think of excluding?

Vibrio: Anne Brisabois: either more strains or delete or just provide information (WGS or DNA)?

-Main action to be done by the person in charge

- Contact the providers, construct a small working group (organize internal meetings)
- Define one contact person per provider institute providing the strains (required for the DMP)
- Define the RM criteria according to the species (we do not have a reference bank to compare with, need to be defined by each species expert)
- Define the essential characterization criteria according to the species (including AMR)
- For each strain, analyze the provided and missing characterization
- For each strain, analyze with the provider the reason of being in the list (ie.: "phenotype eg AMR", or "strains characteristic of reservoir", or "epidemiology (outbreak/sporadic)", etc.)
- Split the strains into the 3 lists
- Precisely list the missing characterization for each strain (including AMR)
- Define with each provider their capacity to fill the gap (*NGS, MALDI, AMR, phenotyping...*)
- Note the strains for which characterization by the provider will not be possible (to ask for feasibility by the other participants involved in Task 3)

No limitation of strain number at this stage: this first round will help define the number of strains to include in Task 3

Feed back to the group before the 26 of February

Next conf call on WP2-Task 2/3 in march

Keep in close contact with WP3.

Questions

- Susanne could you please send a reminder if anyone would like to join the expert board
- We propose to exclude 2 species because of lack of strains and/or difficulty to provide some species: Vibrio and Streptococcus
- If ok, we focus on the other 7 (already a lot of work!). If those species are absolutely required we may propose for some strains not to provide the strains, but only information (WGS...) or DNA.

-The “optional list” can be mentioned in the CARE catalog without the mark “reference material” and made available by any of the partner volunteer to do it. If some time/funds available after dealing with the short list strains, these second list strains could be also upgraded with new characterization depending of what is missing.



-Each institute is supposed to be able to provide the strains. But the professional BRC propose to take the short list in collection (Number and conditions to be discussed).

Risk and Mitigation

A small delay in Task 2 in 2020, but will be ok in 2021

No risk identified for the next step

To be reconsidered for Task 3

Especially need for discussion about the standardization of protocols and methods

Link with other EJP Projects

Listadapt and Toxdetect



Appendix: Minutes from WP3 breakout session

Chair: Michel-Yves Mistou

Outcome: Major Actionable tasks to be done:

- Conduct a first general meeting to build Working Groups (WGs) dedicated to T1,T2,T3 and identify people to be involved
- Assign tasks Task to each WG, setting their meeting rhythms and their provisional objectives.
- Set a schedule for regular meetings with WP2 to finalize RMs and associated information
- Set a meeting schedule with WP1 to align relevance of RMs
- Obtain information from Beta-testers WG about website functionalities
- Training material content
- Address conservation and distribution issues (logistic, financial)
- Address sustainability issues
- Update GANTT chart for risk management

PROCEEDINGS

Main Objectives for each task

1. Remind milestones and deliverables for 2021
2. Identify partners and decide involvement of each partner in the activities
3. Revise and validate GANTT chart for the WP
4. Confirm data generated by the WP for the DMP
5. Speculate Risk and mitigation (COVID-19 related and others)
6. Share Reflections on links to other OHEJP projects and how to conduct valorization/publications

Discussions

For Task 1: Searchable online catalog > Oct 2021

- Validate and integrate RM information from WP2 into the database
- Define functionalities and Web portal development
- DMP

Task leader: MY Mistou - INRAE

Deputy: Magdalena ZAJAC - PIWET

1. Milestones and deliverables for 2021

- Deliverable 3 - Searchable online RMs catalog by Oct., 2021
- The volume of RM not decided by WP2 yet, column to be added for 'why is it included as RM'
- Subgroups created by WP2 to explore missing info and other characterization capabilities of partners
- Shrink the list - e.g., Salmonella, perhaps exclude Vibrio, Strep (not enough isolates)
- We may not start validating and integrating information for all species in parallel, but rather one by one starting with the most consistent data
- Involvement of each partner in the activities > contact person/partner



- Forum Shah to be the coordinator for Task 1
- 1st proposal to define working groups (with committed people) to work on:
 - ❖ Coordination with WP1 (remain aligned with the vision) and WP2 (every week ?) for the beta-list of RM and PTs (Volume expected ?) The leader for each species will be POC for WP3
 - ❖ Work on rules and ontology to fill in the 37 fields of the DB (ex: Bibliography, Geography, Origin, phenotypes (AMR), WGS accession ...). 17 mandatory fields which will be specific to 'Why' for RM. For other fields, refer to rules from other databases (ex. MIRRI). WP3 will make proposals about it, and request partner recommendations.
 - ❖ Website functionality - Take inspiration from websites, seek feedback from users, Rene may propose a functionality wishlist, to which others can contribute. In a survey, share some interesting websites and get opinions on what is good, bad and can be improved. Consider not just the end users but also the data management team.
 - ❖ Beta-testing group of users

Reach out to partners who have not contributed much to CARE yet, call in regular meetings, perhaps roll out a survey (include WP3 team ideas and explore other ideas). Host task-specific meetings.

3. Revision and validation of GANTT chart for the WP: A detailed GANTT chart can help anticipate risks & allow to see delays early on. Example proposed by Rene as below:

Preparatory activity		Overall Gantt Chart		EJP CARE											
Data collection activity				FIRST ANNUAL PERIOD 2020						SECOND ANNUAL PERIOD 2021					
Deliverable activity				First project description											
Task activity number	Task activity	Responsible	Measurable outcomes	M25-26	M27-28	M29-30	M31-32	M33-34	M35-36	M37-38	M39-40	M41-42	M43-44	M45-46	M47-48
W1-T2-ST2-1	Collect propose via feedback from WP 4 (risk assessment) the MLSTs, serotypes, virulence	WBWR	Collect the list of target epidemiological markers and traits for		v	v									
W1-T2-ST2-2	Consultation with all partners in IA 2.1-W1-T2-ST2 to obtain consensus agreement of what EQA candidates to search for and included based on the risk assessment list provided.	WBWR	Mutual agreement to EQA candidate profile			v									
W1-T2-ST2-3	Request candidates for the tasks IA 2.1-W1-T2-ST2, genomic EQA to WP 2/3 based on the candidate profiles.	WBWR	List of potential EQA candidates and data / strain owners				v								
W1-T2-ST2-4	Modify and sign MTA	DTU	MTA's signed					ongoing							
W1-T2-ST2-5	Provision of EQA candidates	DTU	EQA strain material received.					v							
W1-T2-ST2-6	Purify DNA of the six EQA candidates for MiSeq sequencing and dispatch to WBWR for complete the genomes.	DTU	The DNA dispatched to WBWR					v							
W1-T2-ST2-7	Close the genome of the EQA candidates	DTU	DTU will received from the US FDA closed genomes of the six candidate strains.						ongoing						
W1-T2-ST2-8	Propagation of cultures and corresponding DNA for dissemination	WBWR	Cultures and DNA produced for dissemination among partners												
W1-T2-ST2-9	Proposal for EQA	DTU	Proposed quality assurance scheme.				v								
W1-T2-ST2-10	Modify DTU informatic EQA modules for CARE purposes and according to the agreed proposal	DTU	The Informatic EQA modules modified to test for the epidemiological markers and traits decided upon.						v						
W1-T2-ST2-11	Provision of expected reference values	DTU, ISS, RIVM, SVA	All expected values included the DTU informatic modules.												
W1-T2-ST2-12	Provide EQA supporting documents and guidelines	DTU	Guidance document dissimilated among partners												
W1-T2-ST2-13	Disseminate pre-notification	DTU	Pre-notification forwarded to partners to alert receipt of EQA material												
W1-T2-ST2-14	Disseminate the produced EQA material	WBWR	EQAS material dispatched to all participating partners												
W1-T2-ST2-15	Analysis of the submitted data	DTU, ISS, RIVM, SVA	Individually EQA report dissimilated incl. technical recommendations in case of incompatible or incorrections												
W1-T2-ST2-16	Summary EQA report developed	DTU	Summary report issued, disseminated and posted on the CARE website												D.1.2.3

4. Data generated by the WP for the DMP

- Include the data from surveys in the DMP
- Data from WP2 may be needed to be split as per country.
- The searchable database catalog to be considered different than the RM collection from WP2. Structure of database considered as meta data which may be included in DMP.

5. Risk and mitigation (COVID-19 related and others). Concerns for compliance to Nagoya protocol.

6. Reflections on links to other OHEJP projects and how to conduct valorization/publications: Not EJP but Connection with GGBD / ENOVAT / MIRRI / MIRABANK ?



For Task 2: Ensure the long-term sustainability of Reference Materials collections

Task leaders: MY Mistou, F. Valence - INRAE

Deputy: Magdalena ZAJAC – PIWET

1. Milestones and deliverables for 2021

- Deliverable 3.2.1: Deposition of RMs within mBRCs and collections considered as “reference collections” by March, 2022
- Milestone: Organize Training session on microbial collection management July, 2021. Discuss how can Training sessions be COVID friendly (like theoretical training and problem-solving sessions, etc). Determine what kind of participants, explore their expectations to shape the training accordingly, prepare training content.

2. Involvement of each partner in the activities

Working groups to work on :

- Defining Reference Collection – Writing a Chart (Rules of Operation / Answers to users / ...)?
- List of collection wishing to be considered as reference collection for Conservation and Distribution of RMs
- Construction of the training program for voluntary collections and the modalities of the training program (webinars, face-to-face) > Important role of certified mBRCs (CRBIP Institut Pasteur, CIRM, INRAE) DATE ?

4. Data generated by the WP for the DMP: Reference collection chart / Training materials /

5. Risk and mitigation (COVID-19 related and others): Organization of the training session – To be postponed for F2F training sessions?

For Task 3: Ensure long-term accessibility of the RM collection and its existence

Task Leader: Mery Piña - Institut Pasteur

Deputy: Maria Beatrice Boniotti - IZSLER

1. Milestones and deliverables for 2021

Deliverable 3.3.1: Signing of an MoU to ensure the sustainability of the CARE IS, June, 2022

2. Involvement of each partner in the activities

Create working groups for:

- Drafting MoU to be circulated between partners and their stakeholders taking care of the different aspects of the CARE sustainability on the long-term: IS sustainability, RM collections sustainability, HR dedicated to CARE sustainability
- Anticipate all aspects of running the CARE RMS on the long-term
- Make clear financial evaluations for task 3 to provide idea of sustainability to stakeholders.



Appendix: Minutes from WP4 breakout session

Chairs: Laurent Guillier, Henk Aarts

Participants: Juliana De Oliveira Mota, Laurent Guillier, Jeppe Boel

WP4-T1 Data and metadata available for risk assessment

Task 1.1. It was decided to extent the possibility to answer the survey till. A final reminder has been sent beginning February.

For task 1.2 that deals on the connection of this CARE activity with the databases and initiatives already in place:

- Organize a meeting with EJP RADAR
- Sent an invitation of stakeholders (EFSA and ECDC) for a meeting in June.
- Invite EJP RADAR, DISCOVER and JIP ORION to this meeting
- Postpone the deliverable (better materialized with the meeting with stakeholders or other projects)

The Gantt chart has been revised to account the modification of Task 1.2 (see below).

Task 1.3 (analysis of the survey on available data) will be presented during the stakeholders meeting. A presentation to the EJPOH conference in June is planned as well. The results of the survey will be part of the DMP of CARE.

The plan for task 2 is difficult to establish in the situation. Further discussions with DTU will be conducted with Rene and Susanne to check how the two deliverables will be planned in 2021.

Preparatory activity		Overall Gantt Chart		EJP CARE														
Data collection activity				FIRST ANNUAL PERIOD 2020					SECOND ANNUAL PERIOD 2021					THIRD ANNUAL PERIOD 2022				
Deliverable activity				First project description					Second project description form					Third project description form				
Task activity number	Task activity	Responsible	Measurable outcomes	M25-26	M27-28	M29-30	M31-32	M33-34	M35-36	M37-38	M39-40	M41-42	M43-44	M45-46	M47-48	M49-50	M51-52	M53-54
				Jan-Feb	Mar-Apr	May-Jun	Jul-Aug	Sept-Oct	Nov-Dec	Jan-Feb	Mar-Apr	May-Jun	Jul-Aug	Sept-Oct	Nov-Dec	Jan-Feb	Mar-Apr	May-Jun
WP4																		
WP4-T1																		
WP4-T2																		
WP4-T3																		
W4-T1-ST1-1	Define the list of targeted institutes to who the survey will be addressed	RIVM, ANSES	File with the list of institutions (together with contact persons) involved in risk assessment throughout Europe		M.4.1.1													
W4-T1-ST1-2	Definition of criteria to assess the data quality and accessibility	ANSES	Criteria to consider in the survey justified by bibliography		M.4.1.2													
W4-T1-ST1-3	Definition of types of risk assessment and associated metadata	ANSES	Categories of risk assessment defined with formal definition		M.4.1.3													
W4-T1-ST1-4	Draft survey on (meta-)data relevant for risk assessment sent to a small group	RIVM, ANSES, USAM	Returned questionnaires by tester			M.4.1.4												
W4-T1-ST1-5	A survey on (meta-)data relevant for risk assessment	RIVM, ANSES	Questionnaire on the survey sent to selected institution				D.4.1.1											
W4-T1-ST2-1	Establish a link with other JIP/EJP projects and other EU initiative (e.g. EFSA Knowledge Junction, RAKIP...)	ANSES, DTU	Letter to take contact with other project leaders							M.4.1.5								
W4-T1-ST2-2	Meeting different partners of these project to check for synergy and to avoid duplication of the work	ANSES	Teleconference organized									M.4.1.6 (D.4.1.2)						
W4-T1-ST3-1	Analysis of the questionnaire	ANSES	Report on analyzed survey data regarding the quality and accessibility							M.4.1.7	M.4.1.8		D.4.1.3					
W4-T2-1	Description on how to access the available data	DTU	User guide to access relevant data										D.4.2.1					
W4-T2-2	Strategy to raise awareness by EU authorities of collecting relevant and high quality data for risk assessment	DTU	Report presenting the strategy for relevant data for risk-assessment											D.4.2.2				
W4-T2-3	Web based exchange platform including antimicrobial	DTU	Available prototype												D.4.2.3			
W4-T3-1	Dissemination plan	ANSES	Excuted dissemination plan							M.4.3.1						M.4.3.2		D.4.3



Appendix: Meeting agenda

Wednesday, 3rd of February 2021

14:00	Day 1, Plenary session	
	Welcome & Introduction (10') incl. virtual housekeeping	Rene Hendriksen DTU, DK
	Overview and links between OHEJP projects 15'	Karin Artursson, SVA
	Follow-up on 12 M report 15'	Rene Hendriksen
	Progress and outcome of WP1, WP2, WP3, WP4 (20' X 4 including questions) WP1 including presentation of 'Develop of cross-sectional PT's (proficiency testing) - Mapping of existing and proposals for new PT schemes' (deliverable of WP1) 10' WP2 including presentation of 'Inventory of the reference materials' (deliverable of WP2) 10'	WP leaders Lucas Wijnands, RIVM, NL Anne Brisabois ANSES, FR
15:45	Break	
16:00	WP3 Towards the construction of an information system for the CARE catalogue of reference materials WP4 Survey on (publicly) accessible (meta-)data for Risk Assessment Interaction between WP4 and other WPs: "Strain Select: an R-tool for sampling strains based on metadata in a One Health context"	Michel-Yves Mistou INRAE, FR Laurent Guillier ANSES, FR
16:50	Presentation of the overall OHEJP program 15'	Hein Imberechts SCIENSANO, BE
17:05	Presentation of DISCOVER project	Kaye Burgess, TEAGASC, IE
17.20	End of the first day	



Thursday, 4th of February 2021

9:00	Day 2, Plenary session		Rene Hendriksen
	Introduction to the day Introduction to discussion items		
9:10	Breakout sessions Discussion items: <ul style="list-style-type: none"> - Milestones and deliverables for 2021 - Involvement of each partner in the activities - Revision and validation of GANTT chart for the WP - Data generated by the WP for the DMP - Risk and mitigation (COVID-19 related and others) - Reflections on links to other OHEJP projects and how to conduct activities in complementary and not in duplication 		
9:10 (75' including time for preparing output)	WP1	WP2	WP leaders and participants
10:25	Break		
10:40 (75' including time for preparing output)	WP3	WP4	WP leaders and participants
12:00	End of breakout sessions		
	Lunch time		
13:30	Day 2, Plenary session		
	Updating actions for each WP and discussion (around 20' per WP)		WP leaders and co-leaders
	Presentation of the Data Management Platform and discussion for CARE 15'		Mia Torpdahl
15.15	General discussion, risks and mitigations, planning and other considerations (30') Conclusion		Facilitator: Rene Hendriksen
15.45	End of meeting		

--- --- ---